National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- (-) Arthritis (7)
- Cancer: Breast Cancer (1)
- Comparative Effectiveness (1)
- Digestive Disease and Health (1)
- Elderly (1)
- Electronic Health Records (EHRs) (1)
- Healthcare Utilization (1)
- Heart Disease and Health (1)
- (-) Medication (7)
- Outcomes (2)
- Patient-Centered Outcomes Research (1)
- Patient Adherence/Compliance (1)
- Quality Measures (1)
- Registries (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 7 of 7 Research Studies DisplayedSchmajuk G, Tonner C, Miao Y
Folic acid supplementation is suboptimal in a national cohort of older veterans receiving low dose oral methotrexate.
The authors aimed to determine the prevalence, predictors of, and persistence of folic acid use in a population-based cohort of methotrexate (MTX) users with rheumatic diseases. They found that patients who did not see a rheumatologist were 23% less likely to receive folic acid compared to patients who did have a rheumatologist visit during the baseline period, and after 20 months, only 50% of patients continued to receive folic acid. The authors recommend improving patient safety for users of MTX by standardizing workflows for folic acid supplementation.
AHRQ-funded; HS024412.
Citation: Schmajuk G, Tonner C, Miao Y .
Folic acid supplementation is suboptimal in a national cohort of older veterans receiving low dose oral methotrexate.
PLoS One 2016 Dec 15;11(12):e0168369. doi: 10.1371/journal.pone.0168369.
.
.
Keywords: Elderly, Healthcare Utilization, Medication, Arthritis
Herrinton LJ, Harrold L, Salman C
Population variations in rheumatoid arthritis treatment and outcomes, Northern California, 1998-2009.
This study assessed variations in rheumatoid arthritis treatment and outcomes at the community level from 1998 through 2009. It found that disease-modifying anti-rheumatic drug use increased in the typical patient from 38 to 63 percent of the time, and oral prednisone use declined from 23 to 15 percent of the time, whereas opioid use initially rose but then fell to 23 percent of the time.
AHRQ-funded; HS019912; HS010391; HS021590; HS018517; HS017919.
Citation: Herrinton LJ, Harrold L, Salman C .
Population variations in rheumatoid arthritis treatment and outcomes, Northern California, 1998-2009.
Perm J 2016 Winter;20(1):4-12. doi: 10.7812/tpp/15-028.
.
.
Keywords: Arthritis, Medication, Comparative Effectiveness, Outcomes
Yazdany J, Robbins M, Schmajuk G
Development of the American College of Rheumatology's rheumatoid arthritis electronic clinical quality measures.
The researchers sought to develop and test electronic clinical quality measures for rheumatoid arthritis. Disease activity assessment, functional status assessment, disease-modifying antirheumatic durg use, and tuberculosis screening measures have achieved national endorsement and are recommended for use in federal quality reporting programs.
AHRQ-funded; HS024412.
Citation: Yazdany J, Robbins M, Schmajuk G .
Development of the American College of Rheumatology's rheumatoid arthritis electronic clinical quality measures.
Arthritis Care Res 2016 Nov;68(11):1579-90. doi: 10.1002/acr.22984.
.
.
Keywords: Electronic Health Records (EHRs), Medication, Quality Measures, Arthritis, Outcomes
Mamtani R, Clark AS, Scott FI
Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study.
The researchers examined the rates of breast cancer recurrence in patients with immune-mediated disease and treated breast cancer who received therapy with methotrexate, thiopurines, or anti-tumor necrosis factor (anti-TNF). They found that the risk of breast cancer recurrence in patients who received methotrexate, thiopurine, or anti-TNF therapy was not statistically significantly increased, although they did not rule out a 2-fold or greater increased risk in those treated with thiopurines.
AHRQ-funded; HS021110; HS018517.
Citation: Mamtani R, Clark AS, Scott FI .
Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study.
Arthritis Rheumatol 2016 Oct;68(10):2403-11. doi: 10.1002/art.39738.
.
.
Keywords: Cancer: Breast Cancer, Digestive Disease and Health, Medication, Patient-Centered Outcomes Research, Arthritis
Curtis JR, Bharat A, Chen L
Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry.
To determine the extent to which methotrexate (MTX) adherence is overestimated by rheumatologists, the researchers deployed an Internet survey to patients with rheumatoid arthritis (RA) participating in a US registry. They found that MTX use was misclassified for 13-20 percent of patients, mainly because of 1 or more missed doses rather than overt discontinuation. Clinicians should be aware of suboptimal adherence when assessing MTX response.
AHRQ-funded; HS018517.
Citation: Curtis JR, Bharat A, Chen L .
Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry.
J Rheumatol 2016 Jun;43(6):1027-9. doi: 10.3899/jrheum.151136.
.
.
Keywords: Arthritis, Patient Adherence/Compliance, Medication, Registries
Pappas DA, John A, Curtis JR
Dosing of intravenous tocilizumab in a real-world setting of rheumatoid arthritis: analyses from the corrona registry.
The objective of this analysis was to describe patterns of early intravenous tocilizumab (TCZ) dose escalation in a real-world setting using data from the Corrona registry. It determined that of the 213 patients who were eligible for analysis, 86 (40.4 percent) remained on their initial dose of TCZ 4 mg/kg and 110 (51.6 percent) were escalated to TCZ 8 mg/kg by or at 3 months.
AHRQ-funded; HS018517.
Citation: Pappas DA, John A, Curtis JR .
Dosing of intravenous tocilizumab in a real-world setting of rheumatoid arthritis: analyses from the corrona registry.
Rheumatol Ther 2016 Jun;3(1):103-15. doi: 10.1007/s40744-016-0028-0.
.
.
Keywords: Arthritis, Medication, Registries
Charles-Schoeman C, Wang X, Lee YY
Association of triple therapy with improvement in cholesterol profiles over two-year followup in the treatment of early aggressive rheumatoid arthritis trial.
The researchers evaluated long-term changes in cholesterol levels in patients with early rheumatoid arthritis (RA) who were randomized to begin treatment with methotrexate (MTX) monotherapy, MTX plus etanercept, or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) . Triple therapy was strongly associated with higher levels of HDL cholesterol, lower levels of LDL cholesterol, and higher ratios of total cholesterol.
AHRQ-funded; HS018517.
Citation: Charles-Schoeman C, Wang X, Lee YY .
Association of triple therapy with improvement in cholesterol profiles over two-year followup in the treatment of early aggressive rheumatoid arthritis trial.
Arthritis Rheumatol 2016 Mar;68(3):577-86. doi: 10.1002/art.39502.
.
.
Keywords: Arthritis, Heart Disease and Health, Medication